Brief CommunicationHematopoietic stem cell transplantation conditioning with use of rituximab in EBV related lymphoproliferative disorders

- We report on rituximab-based HSCT conditioning in 3 patients with XLP and one with ITK deficiency.
- High rates of survival, engraftment and immunological reconstitution are demonstrated.
- None of the patients developed chronic GvHD.
- Rituximab based HSCT in these patients seems to be a reasonable treatment.

X-linked lymphoproliferative disease (XLP) and IL-2-inducible T cell kinase (ITK) deficiency are rare immunodeficiencies with a spectrum of clinical manifestations. Although there are no official guidelines for allogeneic hematopoietic stem cell transplantation (HSCT) in these patients, previous reports have shown that reduced intensity conditioning regimens provide successful engraftment with limited toxicity.Here, we report on three children with XLP and one with ITK deficiency, who underwent successful HSCT using a rituximab containing conditioning regimen, and review the current literature.